[HTML][HTML] Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
X Zhou, Q Xiao, D Fu, H Zhang, Y Tang… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …
Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway
Background The therapeutic potency of Rigosertib (RGS) in the treatment of the
myelodysplastic syndrome has been investigated previously, but little is known about its …
myelodysplastic syndrome has been investigated previously, but little is known about its …
A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity
Approximately 45% of colorectal cancers harbor mutations in the KRAS gene, resulting in
constitutive activation of RAS signaling through effector proteins, primarily RAF and PI3K …
constitutive activation of RAS signaling through effector proteins, primarily RAF and PI3K …
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Targeting KRAS oncogene for patients with colorectal cancer: A new step toward precision medicine
KRAS mutations are common driver oncogenes associated with the development of several
solid tumors. KRAS oncogene has been considered a highly challenging target for drug …
solid tumors. KRAS oncogene has been considered a highly challenging target for drug …
KRAS as Potential Target in Colorectal Cancer Therapy
Colorectal cancer (CRC) is among the most commonly diagnosed cancers affecting both
genders in the world. It is characterized by genetic instability, which drives tumor formation …
genders in the world. It is characterized by genetic instability, which drives tumor formation …
Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer
A Bahrami, SM Hassanian… - Journal of cellular …, 2018 - Wiley Online Library
The V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently
dysregulated in colorectal cancer (CRC). It is involved in the modulation of several …
dysregulated in colorectal cancer (CRC). It is involved in the modulation of several …
[PDF][PDF] Research progress on KRAS mutations in colorectal cancer
M Cefalì, S Epistolio… - J. Cancer …, 2021 - pdfs.semanticscholar.org
The RAS gene family, responsible for signal transduction within the mitogen activated
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways, is frequently …
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways, is frequently …
Targeting KRAS G12C mutations in colorectal cancer
MH Zhao, AW Wu - Gastroenterology Report, 2023 - academic.oup.com
With the advent of Kirsten rat sarcoma viral oncogene homologue G12C (KRAS G12C)
inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new …
inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new …
KRAS mutation‐independent downregulation of MAPK/PI3K signaling in colorectal cancer
KRAS is a gatekeeper gene in human colorectal tumorigenesis. KRAS is 'undruggable';
hence, efforts have been diverted to inhibit downstream RAF/MEK/ERK and PI3K/Akt …
hence, efforts have been diverted to inhibit downstream RAF/MEK/ERK and PI3K/Akt …